Cavalier M, Shmalo J A, Yu M, Billings S D, Abonour R, Nelson R P
Department of Pediatric Hematology/Oncology, Indiana University School of Medicine, 535 Barnhill Drive, Indianapolis, IN 46202, USA.
Bone Marrow Transplant. 2006 Jun;37(12):1103-8. doi: 10.1038/sj.bmt.1705362.
Squamous cell carcinoma (SCC) is the most common skin cancer in patients receiving immunosuppressive therapy, and is well documented to occur in patients that have undergone either solid organ transplantation or conventional myeloablative bone marrow transplantation. Nonmyeloablative hematopoietic cell transplantation (NMAT) provides transient, intensive immunosuppression, permitting allogeneic engraftment without ablating the marrow. The purpose of this report is to describe six patients that developed SCC (n=3), basal cell carcinoma (n=2), or malignant melanoma (n=2) over a period of 2-26 months following NMAT. All patients had myelodysplasia or acute myelogenous leukemia prior to transplantation. The authors demonstrate for the first time that patients who undergo NMAT are at risk for developing skin cancers and emphasize the need for close surveillance in the post transplantation period.
鳞状细胞癌（SCC）是接受免疫抑制治疗患者中最常见的皮肤癌，并且有充分记录表明其发生于接受实体器官移植或传统清髓性骨髓移植的患者。非清髓性造血细胞移植（NMAT）提供短暂、强烈的免疫抑制，允许异体植入而不破坏骨髓。本报告的目的是描述6例在NMAT后2至26个月内发生鳞状细胞癌（n = 3）、基底细胞癌（n = 2）或恶性黑色素瘤（n = 2）的患者。所有患者在移植前均患有骨髓增生异常综合征或急性髓性白血病。作者首次证明接受NMAT的患者有发生皮肤癌的风险，并强调在移植后阶段进行密切监测的必要性。
